Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Mindbio Therapeutics Corp. ( (TSE:MBIO) ).
MindBio Therapeutics has launched an extended showcase in the United States of its voice-activated, AI-powered intoxication detection technology as its shares begin trading on the OTCQB Market. Built on more than 50 million data points from clinical trials, the company’s proprietary algorithms can predict alcohol and hallucinogenic intoxication, estimate blood alcohol concentration via its Booze AI app, and are being developed into an enterprise platform for large-scale, non-invasive drug and alcohol testing in regulated workplace environments such as mining, aviation, and construction, as well as in call centres, mental health services, and law enforcement, positioning MindBio to tap into the emerging market for voice-based health diagnostics.
More about Mindbio Therapeutics Corp.
MindBio Therapeutics Corp. is a Vancouver-based biotechnology company focused on clinical drug and alcohol research and the development of AI- and machine-learning-driven health prediction technologies. Leveraging expertise in speech analytics, the company has created a voice- and AI-powered prediction model for drug and alcohol intoxication designed for both consumer and enterprise use, targeting sectors such as workplaces, law enforcement, mental health, and telehealth.
Average Trading Volume: 3,805
Technical Sentiment Signal: Hold
Current Market Cap: C$2.02M
For a thorough assessment of MBIO stock, go to TipRanks’ Stock Analysis page.